***Background.*** IAI and SW infections present major challenges for hospitalized patients. Monitoring the resistance profiles expressed by the causative organisms is important. Therefore, data from the Tigecycline European Surveillance Trial (TEST) program were analyzed for the resistance patterns observed throughout Europe.

***Methods.*** Isolates were collected and tested locally by broth microdilution according to appropriate CLSI guidelines. **Results** of this study were based on isolates tested from 26 European countries from 2004 -- 2013.

***Results.*** See table.

                                 Antimicrobial: Percent Susceptible: IAI/SW^a^                                                            
  ------------------------------ ----------------------------------------------- --------- --------- --------- -------- --------- ------- ---------
  *Acinetobacter* spp 163/1546   na/na                                           66/70     na/na     28/35     50/58    53/70     45/55   na/na
  *Enterobacter* spp 615/2478    96/96                                           98/98     2/4       53/65     84/89    96/98     68/78   na/na
  *E. coli* 1122/1748            100/100                                         99/99     38/32     84/76     74/64    99/100    91/90   na/na
   ESBL 128/311                  100/100                                         94/96     na/na     na/na     25/22    98/99     74/73   na/na
  *K. pneumoniae* 485/1156       97/96                                           96/95     2/3       75/67     79/73    95/93     78/76   na/na
   ESBL 82/266                   94/96                                           88/88     na/na     4/0       89/34    89/88     32/43   na/na
  *P. aeruginosa* 367/2439       na/na                                           93/93     na/na     na/na     70/67    65/76     76/75   na/na
  *S. marcescens* 101/861        94/96                                           99/98     5/4       78/83     93/93    96/99     87/94   na/na
  *E. faecalis* 366/1067         100/100                                         na/na     98/99     na/na     74/8     na/na     na/na   98/99
  *E. faecium* 381/356           100/100                                         na/na     21/17     na/na     17/17    na/na     na/na   91/90
  *S. aureus,* MSSA 100/3250     100/100                                         na/na     na/na     na/na     95/92    na/na     na/na   100/100
  *S. aureus,* MRSA 42/1302      100/100                                         na/na     na/na     na/na     12/16    na/na     na/na   100/100
  *S. agalactiae* 27/955         100/100                                         100/100   100/100   100/100   100/98   100/100   na/na   100/100

A na = breakpoints not defined or non-applicable, TIG (tigecycline; FDA breakpoints), AK (amikacin), AMP (ampicillin), CFT (Ceftriaxone), MER (meropenem), LEV (levofloxacin) PT (piperacillin/tazobactam), VAN (vancomycin)

***Conclusion.*** Against *Enterobacteriaceae*, including ESBL-producers, TIG, AK and MER were the most active agents; against gram-positive cocci TIG resistance was not encountered. For *Acinetobacter* spp. all agents demonstrated poor activity; against *P. aeruginosa* AK and PT were the most active agents. Given the propensity of the bacteria associated with IAI and SW infections, continued monitoring of antimicrobial activity in Europe is warranted.
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